T cells can be engineered to target tumor cells by transduction of tumor-specific chimeric receptors, consisting of an extracellular antigen-binding domain and an intracellular signaling domain. However, the peripheral blood of cancer patients frequently contains an increased number of T regulatory cells, which appear to inhibit immune reactivity. We have investigated the effects of T regulatory cells on chimeric T cells specific for the B-cell antigen CD19, as B-cell malignancies are attractive targets for chimeric T-cell therapy. When a CD19 single-chain Fv antibody was coupled to the CD3 zeta (f) chain, there was sharply reduced activity on exposure to T regulatory cells, measured by CD19 þ target-induced proliferation and cytotoxicity. By contrast, expression in T cells of a chimeric receptor consisting of the intracellular portion of the CD28 molecule fused to the f-chain and CD19 single-chain Fv not only produced a higher proliferative response and an increased nuclear factor jB activation but also sustained these activities in the presence of T regulatory cells. These effects are seen whether the chimeric T cells are derived from normal donors or from patients with B-cell chronic lymphocytic leukemia, indicating the potential for clinical application in B cell malignancies.
Introduction
Although adoptive T-cell therapy holds promise for the treatment of many tumors, applicability is limited by the need to generate high numbers of T cells that are specific for tumorassociated antigens. Because many of these potential target antigens are also expressed on normal cells, tolerance against self-antigens may prevent the ex vivo generation or the in vivo maintenance of adoptively transferred T cells.
One means by which the preparation of tumor-specific T cells may be simplified is by the introduction of a chimeric T-cell antigen receptor (CAR) gene, consisting of an antigen-recognizing domain (antibody single-chain Fv (scFv)) bound to the transmembrane and intracellular part of a signaling molecule (CD3 z-chain). These CAR expressing T cells have been evaluated in a range of preclinical and clinical studies in cancer, multiple sclerosis and in infectious diseases such as human immunodeficiency virus. 1, 2 Although the preparation of such cells may be more feasible than generation of T cells that recognize tumors through their native receptors, several limitations have become apparent. The first of these is the lack of costimulator molecules on target cells that limits the degree of T-cell activation following engagement of the chimeric receptor. As a consequence, effector function is modest and cell division limited. This problem may be addressed by incorporating endodomains from co-stimulator molecules such as CD28 or OX40L, which can compensate for the lack of co-stimulation from the target tumor cell. 1, 3 An additional problem nonetheless remains. Most potentially immunogenic tumors have evolved strategies of immune evasion. Some of these passive strategies, such as downregulation of the major histocompatibility complex (MHC) molecules required for tumor antigen presentation, are irrelevant to recognition by chimeric T cells in which the specific receptor is derived from an antibody molecule. However, active strategies are also used, which may involve the direct secretion of inhibitory cytokines such as transforming growth factor-b (TGF-b) or the recruitment of T regulatory cells (Treg), which may themselves generate an inhibitory environment. 4, 5 Treg cells likely exist within all lymphocyte subclasses, but it is the CD4 þ CD25 þ subset of Treg, which have been most exhaustively documented. 4, 6 In addition to CD4 and CD25 high , these cells also express the transcription factor Foxp3 at high level, 7 and can be derived from naive CD4 þ T cells in response to cytokines such as interleukin (IL)-10 and TGF-b. As many tumor cells secrete TGF-b, naive CD4 þ T cells encountering the malignancy may differentiate into Treg cells, which diminish host antitumor effector responses, 5 via cell contact-dependent mechanisms or release of inhibitory cytokines. 8 B-cell chronic lymphocytic leukemia (B-CLL) is an example of a tumor which may be responsive to immune effector mechanisms including T-cell-expressing CARs for the B-cell antigen CD19, but which also recruits Treg. [9] [10] [11] [12] [13] We have therefore examined the effects of Treg on the antitumor effector function of T-cell-expressing CD19 CAR, and shown how incorporation of the CD28 endodomain serves as an effective countermeasure to this tumor immune evasion strategy.
Methods

Cells and their culture
Daudi B cells and K562 erythroleukemia cells (American Type Culture Collection, Manassas, VA, USA) were cultured in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin and 1% Glutamine (Invitrogen, Paisley, Scotland). 293T cells were cultured in Iscove's modified Dulbecco's medium supplemented as above. Peripheral blood mononuclear cells (PBMCs) were prepared by Ficoll centrifugation of either healthy blood donor buffy coat or heparinized blood from B-CLL patients. B cells for co-culture with autologous chimeric T cells were separated from PBMCs using magnetic cell sorting (MACS) beads (anti-CD20) following the company's protocol (Miltenyi Biotech GmbH, Gergisch Gladbach, Germany). Autologous Treg cells were obtained by culturing CD4 þ T cells (MACS bead sorted) in precoated (5 mg anti-CD28: BD Biosciences, San Jose, CA, USA, and OKT-3 Orthoclone (anti-CD3): Cilag Ag Int., Zug, Switzerland) wells in the presence of 10 ng/ml TGF-b (Nordic BioSite, Täby, Sweden) and 80 m/ml recombinant IL-2 (R&D Systems Inc., Minneapolis, MN, USA) as described elsewhere.
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OKT3 stimulation of T cells
PBMCs (5 Â 10 6 ) from healthy donors and B-CLL patients were cultured with OKT3 Orthoclone (anti-CD3) antibodies (1 mg/ml) (Cilag Ag Int., Zug, Switzerland) for 3 days in 10 ml RPMI medium divided into three wells in a 12-well plate. The RPMI medium was supplemented with 10% FBS, 1% penicillinstreptomycin and 1% Glutamine (Invitrogen, Paisley, Scotland). On day 3, 100 m/ml recombinant IL-2 (R&D Systems Inc., Minneapolis, MN, USA) was added and the cells transduced on day 4 with retroviral vector.
Vectors
The SFG-CD19z and SFG-CD19z28 vectors were constructed as follows: the pHBStrep CD19 plasmid provided by Heddy Zola (Adelaide, South Australia), contains the variable domains of CD19 monoclonal antibody FMC-63 assembled as a ScFv molecule. 15 The chRec gene was generated by subcloning of scFv into pRSV-g, provided by Dr Zelig Eshhar (Rehovot, Israel), 16 in frame with a sequence encoding the human immunoglobulin (Ig)G1 hinge domain and the transmembrane and cytoplasmic domains of the Fc receptor g chain. The g chain was then replaced with the corresponding human z chain, which was amplified from pGEM3zz. 17 The chimeric genes were subcloned into the BamH1 and NcoI sites of the retroviral vector SFG provided by Dr RC Mulligan (Cambridge, MA, USA). 18 The human CD28 transmembrane and cytoplasmic domain was cloned from Jurkat cell complementary DNA and subcloned upstream of the T-cell receptor (TcR) z gene while replacing the transmembrane domains of human TcRz to generate CD19-CD28z. A schematic figure of the constructs is shown in Figure 1a . Retroviral vectors were produced by cotransfecting 293T cells with the retroviral vector plasmid (3.75 mg), PeqPam plasmid containing gag-pol (2.5 mg) (gift of Dr Elio Vanin, Baylor College of Medicine, Houston, TX, USA) and RDF plasmid containing the RD114 envelope (3.75 mg) (gift of Mary Collins, London, UK). 19 Briefly, 1.5 Â 10 6 293T cells were cultured in 10 cm Petri dishes overnight. The following day, 470 ml Dulbecco's modified Eagle's medium and 30 ml Gene Juice (Novagene Inc., Madison, WI, USA) were mixed and added to the plasmids. The mixture was incubated 15 min and then added to 293T cells. The viral vector-containing supernatant was harvested 48 h later, whereupon 10 ml fresh medium was added to the 293T cells. The supernatant was harvested a second time 24 h later. The harvested supernatants were snapfrozen with dry ice and isopropanol and stored at À801C.
Transduction of T cells
On day 1, 12-well plates were coated with RetroNectin (TaKaRa Shuzo Co. Ltd, Shiga, Japan) according to the manufacturer's protocol, and stored at 41C. The following day, the plates were coated twice with 0.5 ml retroviral vector supernatant, each added for 30 min at 371C. A total of 7 Â 10 5 OKT3-stimulated T cells/vector were mixed with 2 ml retroviral vector supernatant and transferred to the precoated wells. Recombinant IL-2 (100 m/ml) was added and the plates incubated at 371C. The cells were used for phenotypic analysis, or in cytotoxic assays, from day 7 to day 21 post-transduction. IL-2 was added twice weekly.
Immunocytochemistry
For detection of the TGF-b receptor (TGFbR)-I, -II and -III, CD8 þ cells were enriched using MACS antibody beads (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany) and were cytospun onto glass slides and stained by immunocytochemistry. The following primary antibodies were used: rabbit anti-human TGFbR-I, mouse anti-human TGFbR-II and goat anti-human TGFbR-III (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). For detection of TGFbR-I and -II, ENVISION systems for rabbit and mouse were used (DakoCytomation, Glostrup, Denmark). For detection of TGFbR-III, a rabbit antigoat Ig was used as a secondary step together with Goat PAP (DakoCytomation). The slides were evaluated using a Leica DFC320 imaging system with a Â 40 magnification objective (Leica Microsystems GmbH, Wetzlar, Germany).
Flow cytometry
Cells were phenotyped for cell surface markers using flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA). Monoclonal antibodies against mouse IgG-k light-chain (chimeric receptor)-FITC, CD4-FITC, CD8-APC, CD19-PE, CD25-APC, CD28-F and IL-10 receptor (IL-10R)-PE were all purchased from BD Biosciences. A monoclonal anti-Foxp3 antibody was purchased from Nordic BioSite (Täby, Sweden). To enrich CAR-expressing cells, transduced T cells were stained with the anti-mouse IgG-k light-chain (chimeric receptor)-FITC antibody. The cells were sorted at the Rudbeck Core Facility using a fluorescence-activated cell sorter (BD FACS DiVa, BD Biosciences).
Cytotoxic assays
CD56 þ cells were depleted before the assays using MACSantibody beads (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany). T cells (effectors) were mixed with 51 Cr-labeled target cells (Daudi, K562) at multiple ratios. In experiments assaying Treg activity, the inhibitory cells were added at a 10:1 Treg:Target cell ratio. Recombinant IL-10 (50 ng, BioSource International, Camarillo, CA, USA) or TGF-b (1 mg, Nordic BioSite, Täby, Sweden) were added to the cytotoxicity assays as indicated in the figures. For blocking studies, we used 1 mg each of anti-IL-10 (Nordic BioSite, Täby, Sweden) or anti-TGF-b antibodies (BD Biosciences, San Jose, CA, USA). The cells were cultured in 96-well plates in a total volume of 200 ml RPMI medium for 3 h. After centrifugation the supernatants were collected and the released 51 Cr measured with a gamma counter (Wallac, Turku, Finland). The cytotoxicity (%) was calculated as follows: (sampleÀspontaneous release)/(maximum releaseÀspontaneous release) Â 100.
Cell proliferation assays
Cell growth was determined using the Alamar Blue assay according to the manufacturer's protocol (Biosource International, 
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A Loskog et al (Nordic BioSite, Täby, Sweden) or anti-TGF-b antibodies (BD Biosciences, San Jose, CA, USA) were added. The cell growth was measured by a spectrophotometer at several time points.
Nuclear factor-kB electromobility shift assay Chimeric T cells (0.5 million) were incubated with autologous B cells at a 10:1 ratio. The reaction was interrupted at several time points and the cells lysed with 200 ml lysis buffer (N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid 20 mM pH 7.9, NaCl 50 mM, ethylenediaminetetraacetic acid (EDTA) 10 mM, NP-40 0.5%, dithiothreitol 0.5 mM, sodium fluoride 100 mM and protease inhibitors Complete Mini (Roche, Basel, Switzerland) and kept on ice. The lysate was centrifuged at þ 41C and the supernatant was stored at À201C. The total protein content was determined by Coomassie Plus Protein Assay according to the manufacturer's protocol (Pierce Biotechnology Inc., Rockford, IL, USA). A 20 mg of protein was diluted in 5 Â binding buffer (Tris-HCl 50 mM pH 7.5, glycerol 20%, MgCl 2 5 mM, EDTA 2.5 mM, NaCl 250 mM and 10 U poly (d1-dc)npoly(dI-dc)) and mixed with 1 ml 32 P-labeled nuclear factor kB (NF-kB) oligonucleotide probes (20 000 c.p.m.) (Promega, Southamton, UK). Forward:
For competition, one sample per group was incubated with 4 ml (100 M excess) non-labeled (cold) probe. Samples were resolved by electrophoresis on 5% Tris-borate/polyacrylamide gels. The gels were dried and subjected to autoradiography. The results were quantified by densitometry using Opti Quant Image (Perkin-Elmer, Boston, MA, USA).
Ethical approval
The studies were approved by the Swedish Ethical Committee Dnr: 99337 and by the Baylor College of Medicine Institutional Review Board.
Statistical evaluation
Statistical calculations were performed using Excel Analyse-it Software (Microsoft Corporation, Redmond, WA, USA). Descriptive analyses were performed on continuous data. Student's t-test for one sample or independent (unpaired) samples was used to calculate significant differences to a mean value or among groups.
Results
Transduced T cells have high expression of the CD19 chimeric receptors
PBMCs were stimulated by OKT3/IL-2 and transduced with vectors encoding CD19z or CD19z28 receptors. Expression of the chimeric receptor was detected by using a mouse IgG-k light-chain antibody. As shown in Figure 1b and c, 7 days after transduction the CARs were expressed in T cells at a mean of 20% for CD19z (range 8-24%) and 19% for CD19z28 (range 10-26%). The expression rate was stable as expected of a transferred gene driven by its own promoter. The endogenous expression of CD28 was similar in both CD19z and CD19z28 T cells as shown in Figure 1c . The majority of the transduced T cells were CD8-positive (86%, range 75-96%). Transduction with CD19z-or CD19z28-encoding vectors gave a similar frequency of transgenic CD8 T cells (mean 84%, range 75-93%; and mean 80%, range 74-90%, respectively) (Figure 1d) . Expression of receptors for Treg-related cytokines IL-10 (IL-10R) (Figure 1e ) and TGFbR-II (Figure 1f) was identical on all cell populations, whereas receptors for TGFbR-I and -III were absent.
CD19-redirected T cells lyse CD19 þ target cells
Chimeric T cells expressing scFv CD19z or CD19z28 CARs both lysed CD19 þ Daudi cells, whereas non-transduced T cells did not (Figure 2a) . The addition of the intracellular domain of CD28 to CD19z did not alter the maximum level of killing or enhance the efficacy. The chimeric T cells did not kill CD19 À target cells such as K562 (Figure 2b ) or Daudi cells, in which the CD19 molecule was antibody blocked (Figure 2c) . Hence, CD19-redirected T-lymphocytes kill target cells by recognition of their CD19 antigen and addition of the CD28 endodomain confers no advantage in these cytotoxic assays.
Addition of CD28 intracellular domain enhances proliferation and NF-kB activation of chimeric T cells CD19. T cells were cultured with autologous CD19 þ B cells (at 1:1 and 1:10 ratios) in an Alamar Blue proliferation assay. Figure 3a shows that T cells containing the CD19z28 receptor had an augmented response to autologous B cells compared to T cells expressing only the CD19z receptor (a ¼ 0.01, Po0.0001), which in turn proliferated more than T cells lacking the chimeric receptor (a ¼ 0.01, Po0.0001). Proliferation was also measured by thymidine incorporation assays and complete correlation with these results obtained (data not shown). One of the intracellular mediators of activation following TcR ligation is the transcription factor NF-kB, which is normally bound to the inhibitory kB (IkB) molecule. Upon activation, IkB is released from NF-kB, which then translocates to the nucleus to promote cytokine gene transcription. This process is largely dependent on co-stimulation via CD28. 20 Analysis of chimeric T-cell lysates after incubation with autologous B cells showed that activated NF-kB could more rapidly be detected in T cells transduced with the CD19z28 receptor than in T cells chimeric for the CD19z CAR (o15 min versus 430 min; Figure 3b ). Densitometry plots revealed that the band derived from the CD19z28 cells was twice as strong as the band from CD19z cells at 15 min (Figure 3c ).
Responses of CD19z but not CD19z28 chimeric T cells are diminished by T regulatory cells and inhibitory cytokines
We generated CD4 þ CD25 þ Foxp3 þ Treg cells from CD4 þ T cells by a 5-day culture with TGF-b.
14 In Figure 4a Figure 4c and d), which could be prevented by addition of IL-10 and TGF-b antibodies. IL-10 had no significant effect on CD19z28 T cells. TGF-b had a limited, but nonetheless significant, inhibitory effect on these cells (a ¼ 0.01, Po0.0004). However, the CD19z T cells were more sensitive to TGF-b than CD19z28 T cells (a ¼ 0.01, Po0.0001). Treg cells also had differential effects on the cytotoxic activity of CD19z and CD19z28 CAR T cells. At a T cell:tumor ratio of 30:1, both CD19z and CD19z28 T cells were affected by addition of Treg cells, although the CD19z T cells sustained significantly greater inhibition of their cytotoxicity (a ¼ 0.05, P ¼ 0.019). When the T-cell ratio was increased to 100:1, the significant difference between CD19z and CD19z28 T cells was even greater (a ¼ 0.01, P ¼ 0.0013; Figure 5a) . Similarly, addition of IL-10 decreased the cytotoxicity of CD19z T cells (30-100:1, a ¼ 0.01, Po0.0001), but not of CD19z28 T cells (Figure 5b ). Figure 5c shows that TGF-b was inhibitory to CD19z28 only at T cell:tumor ratios of 30:1 (a ¼ 0.01, P ¼ 0.003), whereas the cytokine inhibited CD19z at all ratios (30:1; a ¼ 0.01, P ¼ 0.0039, 100:1; a ¼ 0.01, P ¼ 0.0053). Significant suppression was abrogated by blocking antibodies to IL-10 or TGF-b. To ensure the apparent effects of the chimeric T cells were not attributable to non-transduced T cells in the cultures, we used FACS to isolate CAR-positive cells. These cells were then used in proliferation and cytotoxicity assays as above. CD19z28 CAR T cells can be generated from B-CLL patients, which will kill autologous tumor cells and are Treg cell resistant
We were able to express the CD19z and CD19z28 CAR in the peripheral blood T cells from 4/5 patients with B-CLL. As in CAR expressing T cells from healthy donors, exposure of these patient CAR T cells to target B-CLL cells induced expression of activated NF-kB. The response was again faster and more prolonged in the CD19z28 than in the CD19z T cells (Figure 7a ). The densitometry plot demonstrates a high stable NF-kB in CD19z28 T cells compared to levels in CD19z T cells (Figure 7b ). Table 1 summarizes the results obtained with patient material.
Discussion
We compared the effects of Treg and the inhibitory cytokines they produce on chimeric T cells engineered to express either the CD19z receptor alone or a CD19z receptor incorporating the signaling domain of the CD28 molecule (CD19z28). Both CD19z and CD19z28 chimeric T cells killed B-cell tumor targets to an equivalent degree. However, the inclusion of CD28 in the chimeric receptor not only augmented NF-kB expression and increased IL-2-independent proliferation when the chimeric T-lymphocytes were exposed to tumor cells but also reduced inhibition produced by Treg cells and the inhibitory cytokines IL-10 and TGF-b.
Optimum activation of T cells requires at least two types of signal. The first is provided via TcR ligation to MHC/peptide, and the second by co-stimulation through an assortment of molecules, of which CD28 appears the most potent. 21 TcR signaling activates the protein tyrosine kinases zeta-associated protein 70 and lymphocyte-specific protein tyrosine kinase, leading ultimately to activation of transcription factors including NF-kB. Following ligation of CD28 by B7 ligands, tyrosine phosphorylation of Gab2 initiates formation of a multimeric 
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A Loskog et al complex involving CD28, Gab2, phosphatidylinositol-3-kinase (PI3K) and Src homology 2 phosphotyrosyl phosphatase. The YMNM motif in the intracellular region of CD28 is phosphorylated, thereby binding the p85 subunit of PI3K, which initiates activation of the phosphatidylinositol molecules 3,4 biphospate (PI(3,4)P 2 ) and 3,4,5-triphospate (PIP 3 ). 22 Co-stimulation via CD28 reduces the levels of the cyclin-dependent kinase p27 Kip1 which may explain increased proliferation in co-stimulated T cells. 23 T cells that lack CD28 activation become anergized. 24 Further, by inducing expression of the antiapoptotic gene Bcl-X L , co-stimulated cells are resistant to apoptosis induction. 21 Finally, TcR stimulation without CD28 is insufficient to promote histone acetylation or cytosine demethylation, thereby limiting access to promoter/enhancer regions for cytokine genes such as IL-2.
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After the first round of T-cell activation, CD28 co-stimulation is largely completed so that even in the absence of CD28, subsequent recognition via the TcR leads not to anergy but to effector function, including killing of target cells by CD8 þ T cells. However, these effector T cells remain subject to additional inhibitory mechanisms. In a hostile tumor milieu, several cellular and soluble factors such as TGF-b are present which diminish T-cell function, and may resurrect the requirement for co-stimulation by CD28 ligation. 21, 26 Although such additional co-stimulation is provided physiologically by ligation of the native CD28 molecule, the same effects can also be gained by incorporation of the CD28 signaling endodomain into CARs. 27 For example, in a mouse model of colon cancer, syngeneic chimeric T cells with CD28 cured 80% of mice, whereas T cells lacking this endodomain only cured 40%. 28 In immunodeficient mice, T cells with a chimeric receptor incorporating CD28 were better able to delay tumor growth. 29 The mechanisms by which 'secondary' CD28 stimulation enhances eradication of tumor have not been clear, and it has been suggested that the effects have been predominantly to rescue T cells from apoptosis, via induction of Bcl-X L. 30 Our own data now suggest another potential mechanism of benefit, as the effects of CD28 activation via chimeric receptor ligation also extend to protection from Treg cells and the inhibitory cytokines they secrete. Whereas native CD28 on the chimeric CD28 improves chimeric T-cell activation A Loskog et al T cells may also interact with B7 molecules on the targeted B cells, our data show that transgenic CD28 fused into the chimeric receptor can further enhance these processes. Protection from Treg may be of particular importance in the immunotherapy of B-CLL. Whereas continued exploration of immunotherapy for this and related B-cell malignancies is appealing because of the successes of antibody therapy directed to the CD19 and CD20 antigens, B-cell malignancies also induce a high level of Treg, which dampen the effectiveness of such cellular immunotherapy, 9, 13 including the ability of CD19-retargeted T cells to lyse these cells. 12 Our data show that CD19z28 chimeric receptor T cells are not only able to effectively kill autologous tumor targets, but are also able to resist inhibition mediated by Treg. The inhibitory activities of Treg may arise both from the inhibitory cytokines they secrete (including IL-10 and TGF-b), and via incompletely defined cell contact-dependent mechanisms that may include interaction between CTLA4 on the Treg and B7 molecules on the effector T cells. 31 More is known about the inhibitory effect of IL-10 and TGF-b. Ligation of the IL-10R inhibits production of a number of cytokines thereby decreasing the magnitude of activation. 32 As the expression level of IL-10Rs on CD19z and CD19z28 T cells was similar, the greater negative effect of IL-10 on CD19z T cells may depend on differences in the potency of the activation signals. For example, CD19z28 T cells responded faster than CD19z T cells on CAR engagement as measured by activation of NF-kB. TGF-b inhibits the proliferation and effector function of T cells by inhibiting IL-2 production, but also affects cell-cyclerelated proteins and has additional less well-understood inhibitory actions. 33 The enhanced T-cell proliferation and cytokine expression mediated by the CD28 domain in the chimeric T cells evidently allows for a higher threshold for the effects of TGF-b inhibitory signaling, although it does not completely abrogate sensitivity to this agent.
Finally, generation of chimeric T cells from patients with B-CLL seems highly feasible. We were successful in 4/5 patients and these chimeric T cells react with on tumor antigen and Treg cells in the same manner as chimeric T cells from healthy donors. We have shown that addition of the intracellular domain of CD28 to the chimeric receptor may enable the transgenic T cells to escape inhibition by the Treg that circulate in high numbers in these patients. Hence, these chimeric T cells may provide an effective immunotherapy for this and related B-cell malignancies.
